SF-268 Xenograft Model Service for Glioblastoma
The SF-268 xenograft model offers a robust, clinically relevant platform for preclinical evaluation of glioblastoma therapeutics, capturing the aggressive proliferation and therapeutic resistance that define this devastating CNS malignancy. At Alfa Cytology, we provide a fully validated SF-268 Xenograft Model Service tailored to your drug discovery pipeline---from tumor establishment and longitudinal monitoring to histopathological and pharmacodynamic endpoints---ensuring reproducible, GLP-compliant data that accelerates your transition from bench to bedside.
Overview of SF-268 Xenograft Model for Glioblastoma
The SF-268 cell line was originally established from a malignant glioblastoma/astrocytoma specimen and is classified as a Grade IV glioma model within the NCI-60 panel. Genetically, SF-268 exhibits epidermal growth factor receptor (EGFR) mutations and tyrosine deletions, alongside marked anaplastic morphology characterized by poor differentiation and rapid, uncontrolled proliferation. The cell line demonstrates robust resistance to temozolomide via MGMT overexpression and displays pronounced invasiveness, making it a representative model for studying therapy-refractory glioblastoma. In vivo, SF-268 cells reliably engraft in immunodeficient murine hosts, forming aggressive tumors that recapitulate key hallmarks of human glioblastoma, including aberrant angiogenesis driven by ID4 overexpression and dysregulated Hippo/YAP signaling that promotes oncogenic survival and proliferation.
The SF-268 xenograft model has been extensively leveraged in preclinical research to interrogate mechanisms of chemoresistance, evaluate blood-brain barrier-penetrant agents, and assess combination regimens. Notably, studies utilizing this model have demonstrated that flubendazole induces G2/M arrest and apoptosis via p53 upregulation, while fingolimod and levomepromazine exhibit significant antiproliferative effects and synergize with temozolomide. Additionally, the HOTTIP-miR-10b-EMT axis has been elucidated in SF-268 cells as a critical driver of temozolomide resistance, underscoring the model's utility for identifying novel therapeutic targets and stratifying responders from non-responders in precision oncology workflows.
Figure 1. Combination indexes of different compounds with TMZ in different neural tumors cell lines. (Doello, K, et al., 2022)
Cell Line Information: SF-268
The SF-268 cell line is a well-characterized human glioma model with the following attributes:
| Feature |
Specification |
| Cell Line Name |
SF-268 (also referred to as SF268) |
| Species |
Homo sapiens (Human) |
| Tissue Origin |
Central nervous system; brain (parietal lobe) |
| Disease Classification |
Glioblastoma / Anaplastic astrocytoma (WHO Grade IV glioma) |
| Cell Type |
Astrocytic glioma; non-epithelial, anaplastic morphology |
| Age at Diagnosis |
Originally reported as 24 years; subsequent analysis revealed Y-chromosome presence indicating male origin |
| Gender |
Male (corrected from initial female attribution via karyotypic analysis) |
| Morphology |
Highly anaplastic; poorly differentiated; rapid proliferation with high nuclear-to-cytoplasmic ratio |
| Growth Characteristics |
Adherent monolayer; high proliferative index; doubling time approximately 24--30 hours under standard conditions |
| Culture Medium |
DMEM or MEMalpha supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 ug/mL streptomycin; 37 degrees C, 5% CO2 |
| Key Genetic Alterations |
EGFR mutation; tyrosine deletion; YAP oncogene amplification; MGMT overexpression; wild-type PTEN status (relative to SF-295) |
| Molecular Markers |
High ID4 expression (promotes angiogenesis); elevated cytoskeletal and ribosomal protein expression; activated PI3K/AKT and MAPK/ERK signaling |
| Resistance Profile |
Temozolomide resistance (MGMT-mediated); radiation resistance; apoptosis evasion via p53-independent pathways |
| Invasive Potential |
High; exhibits epithelial-to-mesenchymal transition (EMT) markers including ZEB1/ZEB2 upregulation and E-cadherin downregulation |
| Tumorigenicity |
High; forms aggressive subcutaneous and orthotopic tumors in immunodeficient mice (e.g., athymic nude, NOD/SCID) |
| NCI-60 Panel |
Member of the National Cancer Institute's NCI-60 standard screening panel for anticancer compound evaluation |
| Authentication |
STR profiling recommended; authenticated via equivalent short tandem repeat analysis |
| Common Applications |
Drug screening (cytotoxic and targeted agents); mechanism-of-action studies; resistance pathway analysis; combination therapy evaluation; angiogenesis research |
Our Services
Alfa Cytology delivers end-to-end preclinical support for glioblastoma drug development through our validated SF-268 xenograft platform. We combine rigorous cell line authentication, IACUC-regulated animal handling, and GLP-compliant study execution with flexible dosing regimens, multi-route administration, and comprehensive endpoint analyses---including tumor growth inhibition/delay, pharmacokinetic profiling, immunohistochemistry, and bioluminescence imaging---to provide actionable, publication-ready data that de-risks your therapeutic candidates before they enter the clinic.
Workflow of SF-268 Xenograft Model Construction
Construction of the SF-268 xenograft model follows a standardized, reproducible workflow optimized for high tumor take rates and consistent growth kinetics. The process encompasses cell preparation, host selection, implantation, monitoring, and endpoint analysis, ensuring robust data generation for preclinical therapeutic evaluation.
- Cell Preparation and Quality Control: SF-268 cells are expanded under standard culture conditions and harvested at 70--80% confluence. Viability is confirmed by trypan blue exclusion (>=95% viability required), and cell identity is verified via STR profiling. Mycoplasma and pathogen screening are performed to ensure contamination-free inoculum.
- Host Selection and Acclimation: Immunodeficient mice (e.g., athymic nude or NOD/SCID, 6--8 weeks old) are acclimated for 5--7 days in a controlled vivarium environment. Animals are randomized by body weight and examined daily for baseline health status prior to tumor cell injection.
- Tumor Cell Inoculation: For subcutaneous models, SF-268 cells (typically 1x10^6 to 5x10^6 cells in 100--200 uL) are suspended in a 1:1 mixture of serum-free medium and Matrigel to enhance engraftment, then injected into the hind flank using a sterile 25--27G needle. For orthotopic models, cells are stereotactically implanted into the right cerebral hemisphere (e.g., 3x10^5 cells in 5 uL PBS) via a burr hole and Hamilton syringe, with injection coordinates referenced from bregma.
- Post-Operative Monitoring and Tumor Surveillance: Mice are monitored daily for body weight, clinical signs, and tumor appearance. Subcutaneous tumors are measured twice weekly with digital calipers in two perpendicular dimensions, and volume is calculated using the modified ellipsoid formula (V = 0.5 x length x width^2). Orthotopic tumor burden is monitored via bioluminescence imaging (BLI) for luciferase-expressing lines or MRI for non-labeled models.
- Treatment Initiation and Dosing: Once tumors reach 100--150 mm^3 (subcutaneous) or established BLI signal (orthotopic), animals are randomized into treatment and vehicle control groups. Investigational agents are administered via the specified route---oral gavage, intraperitoneal, intravenous, intratumoral, or continuous infusion---according to the study protocol.
- Endpoint Analysis and Sample Collection: Study endpoints include tumor growth inhibition (TGI), tumor growth delay (TGD), survival assessment, and toxicity evaluation. Tumors are excised, weighed, and processed for histopathology (H&E, IHC), gene expression profiling, protein analysis, and pharmacokinetic/pharmacodynamic (PK/PD) studies. Blood chemistry and gross necropsy are performed to evaluate systemic toxicity.
Figure 2. SF-268 xenograft model construction workflow.
Case Study-SF-268 Xenograft Model Development
In a representative preclinical engagement, the SF-268 subcutaneous xenograft model was employed to evaluate a novel small-molecule inhibitor targeting the PI3K/AKT pathway. Following successful engraftment and randomization at mean tumor volumes of 120 mm^3, compound-treated cohorts received daily oral dosing for 21 days. The study demonstrated dose-dependent tumor growth inhibition, with the high-dose group achieving statistically significant tumor growth delay compared to vehicle controls. Pharmacodynamic analyses confirmed target engagement via reduced p-AKT and p-S6 levels in excised tumor tissue, while H&E and Ki-67 immunohistochemistry revealed decreased proliferative index and increased apoptotic bodies. Full datasets, including PK profiles, toxicity panels, and survival curves, are available upon request under confidentiality agreements.
Why Choose Alfa Cytology?
Alfa Cytology offers a differentiated, client-centric approach to SF-268 xenograft model services, combining scientific rigor with operational flexibility to meet the demands of modern drug development programs.
- Validated, authenticated SF-268 cell banks with documented STR profiles and routine mycoplasma screening ensure experimental integrity from day one.
- IACUC-regulated, GLP-compliant vivarium operations guarantee ethical, reproducible, and audit-ready study execution.
- Flexible study designs accommodate subcutaneous, orthotopic, and metastatic engraftment formats with customizable dosing routes and schedules.
- Integrated endpoint capabilities---including tumor growth kinetics, immunohistochemistry, flow cytometry, gene expression, and imaging---deliver comprehensive pharmacodynamic insights.
- Dedicated project management and rapid turnaround times streamline communication, milestone tracking, and data delivery to keep your pipeline on schedule.
- Competitive, transparent pricing models without hidden fees allow precise budget forecasting for preclinical program planning.
Contact Us
Ready to advance your glioblastoma therapeutic program with a validated SF-268 xenograft model? Contact us today to discuss your study objectives, receive a customized proposal, and partner with a CRO committed to delivering robust, translational preclinical data. Please reach out to us today via our inquiry form or email to learn more about our SF-268 Xenograft Model services.
Reference
- Doello, Kevin, et al. "Antitumor effect of traditional drugs for neurological disorders: preliminary studies in neural tumor cell lines." Neurotoxicity Research 40.6 (2022): 1645-1652.
For research use only. Not intended for any clinical use.
